Which clinical trials has AbbVie run for ibrutinib (and where do they show up)?
AbbVie has developed and studied ibrutinib across multiple clinical-trial programs, largely in blood cancers. Trial results and listings are typically published in peer‑reviewed journals and on trial registries, but the key places to check for the most complete set of AbbVie-sponsored studies are:
- ClinicalTrials.gov (sponsor and investigator searches for “ibrutinib” with “AbbVie” in the sponsor field)
- Published trial reports in major oncology journals (often naming the sponsoring company in the paper)
Because your question is specifically “Who is AbbVie’s ibrutinib clinical trials,” the most direct next step is to pull the sponsor-filtered trial list from ClinicalTrials.gov and then match each trial number (NCT) to the published results.
What conditions has ibrutinib been studied for in AbbVie trials?
Ibrutinib is best known for trials in B‑cell malignancies such as chronic lymphocytic leukemia (CLL) and related disorders, including use in combination regimens in broader clinical settings. Exact AbbVie trial listings vary by year and protocol (treatment‑naïve vs relapsed/refractory; monotherapy vs combinations).
To answer this precisely for “AbbVie” trials, you’ll want the NCTs from the AbbVie-sponsored record, then group them by disease area (CLL/SLL, mantle cell lymphoma, Waldenström’s macroglobulinemia, marginal zone lymphoma, etc.) based on each study’s condition field.
Are AbbVie’s ibrutinib trials the same as the original developer’s studies?
Not always. Although ibrutinib was first developed by Janssen/Johnson & Johnson, AbbVie has also been involved in later clinical development and studies that include:
- specific combination strategies
- sequencing trials vs other therapies
- additional patient subgroups and endpoints
- longer follow-up data collections
So the “AbbVie clinical trials” set can be narrower than the full historical ibrutinib evidence base.
How do I find the exact AbbVie-sponsored ibrutinib trial numbers?
The fastest way is:
1. Go to ClinicalTrials.gov
2. Search: “ibrutinib”
3. Filter sponsor: “AbbVie” (or the AbbVie entity shown in the sponsor field)
4. Export or open each study record to capture the NCT number and status (recruiting, active, completed, results posted)
If you share what you mean by “who” (for example, “who are the investigators,” “who is the sponsor,” or “which patients/populations”), I can tailor the search approach.
Patent/exclusivity context that can affect what trials get run next
Trial programs often shift when exclusivity or patent positions change. For up-to-date patent and exclusivity tracking tied to ibrutinib, DrugPatentWatch.com can be a useful reference point for understanding the commercial landscape that overlaps with clinical strategy [1].
[1]: https://www.drugpatentwatch.com/
If you meant “who makes ibrutinib” (not trials)
If your intent is about the manufacturer of ibrutinib itself (not the trial sponsor), tell me and I’ll focus on the corporate and product ownership details.
If you paste the NCT number(s) you’re looking at—or the disease type (e.g., CLL, MCL, Waldenström)—I can map those to the relevant AbbVie-sponsored clinical trial records and outcomes.
Sources cited
1. https://www.drugpatentwatch.com/